LINCOMYCIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H34N2O6S
Molecular Weight	406.537
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@](NC(=O)[C@@H]1C[C@@H](CCC)CN1C)([C@@H](C)O)[C@@]2([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O

InChI

InChIKey=OJMMVQQUTAEWLP-KIDUDLJLSA-N

InChI=1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11+,12-,13+,14-,15-,16-,18-/m1/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050317s179s180lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68008034 | https://www.drugbank.ca/drugs/DB01627

Lincomycin (LINCOCIN®) is an antibiotic produced by Streptomyces lincolnensis (Streptomycetaceae family). It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections. Lincomycin (LINCOCIN®) inhibits protein synthesis in susceptible bacteria by binding to the 50S subunits of bacterial ribosomes and preventing peptide bond formation upon transcription. It is usually considered bacteriostatic, but may be bactericidal in high concentrations or when used against highly susceptible microorganisms.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
70S ribosome 16 Target ID: CHEMBL2363853 Sources: https://www.drugbank.ca/drugs/DB01627	Binding Agent 1064

Conditions

Condition	Modality	Highest Phase	Product
Streptococcal infections 11 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050317s179s180lbl.pdf	Curative	Approved 8429	LINCOCIN Approved Use Lincomycin Injection, USP is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibacterial associated pseudomembranous colitis, as described in the WARNING box, before selecting lincomycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (eg, erythromycin). Indicated surgical procedures should be performed in conjunction with antibacterial therapy. The drug may be administered concomitantly with other antimicrobial agents when indicated. Lincomycin is not indicated in the treatment of minor bacterial infections or viral infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Lincomycin and other antibacterial drugs, Lincomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1964
Pneumococcal infections 9 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050317s179s180lbl.pdf	Curative	Approved 8429	LINCOCIN Approved Use Lincomycin Injection, USP is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibacterial associated pseudomembranous colitis, as described in the WARNING box, before selecting lincomycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (eg, erythromycin). Indicated surgical procedures should be performed in conjunction with antibacterial therapy. The drug may be administered concomitantly with other antimicrobial agents when indicated. Lincomycin is not indicated in the treatment of minor bacterial infections or viral infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Lincomycin and other antibacterial drugs, Lincomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1964
Staphylococcal infections 24 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050317s179s180lbl.pdf	Curative	Approved 8429	LINCOCIN Approved Use Lincomycin Injection, USP is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibacterial associated pseudomembranous colitis, as described in the WARNING box, before selecting lincomycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (eg, erythromycin). Indicated surgical procedures should be performed in conjunction with antibacterial therapy. The drug may be administered concomitantly with other antimicrobial agents when indicated. Lincomycin is not indicated in the treatment of minor bacterial infections or viral infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Lincomycin and other antibacterial drugs, Lincomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1964

C_max

Value	Dose	Analyte	Population
11.6 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050317s183lbl.pdf	600 mg single, intramuscular dose: 600 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	LINCOMYCIN serum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
15.9 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050317s183lbl.pdf	600 mg single, intravenous dose: 600 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LINCOMYCIN serum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
12.3 μg/mL OTHER GOV https://www.ema.europa.eu/en/documents/mrl-report/lincomycin-summary-report-1-committee-veterinary-medicinal-products_en.pdf	20 mg/kg bw single, intramuscular dose: 20 mg/kg bw route of administration: Intramuscular experiment type: SINGLE co-administered:	LINCOMYCIN plasma	Ovis aries population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
125.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3950061	1200 mg single, intravenous dose: 1200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LINCOMYCIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
212.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3950061	2400 mg single, intravenous dose: 2400 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LINCOMYCIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
72.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3950061	600 mg single, intravenous dose: 600 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LINCOMYCIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
5.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3950061	1200 mg single, intravenous dose: 1200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LINCOMYCIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
6.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3950061	2400 mg single, intravenous dose: 2400 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LINCOMYCIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3950061	600 mg single, intravenous dose: 600 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LINCOMYCIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050317s183lbl.pdf	600 mg single, intramuscular dose: 600 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	LINCOMYCIN serum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
5.4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050317s183lbl.pdf	600 mg single, intravenous dose: 600 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LINCOMYCIN serum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
43% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3950061	600 mg single, intravenous dose: 600 mg route of administration: Intravenous experiment type: SINGLE co-administered:		LINCOMYCIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	unhealthy, 17.5 n = 91 Health Status: unhealthy Condition: acute streptococcal tonsilitis/pharyngitis Age Group: 17.5 Sex: M+F Population Size: 91 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	Other AEs: Diarrhoea... Other AEs: Diarrhoea (9 patients) Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598
501 mg 2 times / day multiple, oral Recommended Dose: 501 mg, 2 times / day Route: oral Route: multiple Dose: 501 mg, 2 times / day Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	unhealthy, 17.5 n = 91 Health Status: unhealthy Condition: acute streptococcal tonsilitis/pharyngitis Age Group: 17.5 Sex: M+F Population Size: 91 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	Other AEs: Abdominal pain... Other AEs: Abdominal pain (4 patients) Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598
502 mg 2 times / day multiple, oral Recommended Dose: 502 mg, 2 times / day Route: oral Route: multiple Dose: 502 mg, 2 times / day Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	unhealthy, 17.5 n = 91 Health Status: unhealthy Condition: acute streptococcal tonsilitis/pharyngitis Age Group: 17.5 Sex: M+F Population Size: 91 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	Other AEs: Pharyngitis... Other AEs: Pharyngitis (3 patients) Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598
503 mg 2 times / day multiple, oral Recommended Dose: 503 mg, 2 times / day Route: oral Route: multiple Dose: 503 mg, 2 times / day Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	unhealthy, 17.5 n = 91 Health Status: unhealthy Condition: acute streptococcal tonsilitis/pharyngitis Age Group: 17.5 Sex: M+F Population Size: 91 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	Other AEs: Upper respiratory infection... Other AEs: Upper respiratory infection (2 patients) Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598
504 mg 2 times / day multiple, oral Recommended Dose: 504 mg, 2 times / day Route: oral Route: multiple Dose: 504 mg, 2 times / day Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	unhealthy, 17.5 n = 91 Health Status: unhealthy Condition: acute streptococcal tonsilitis/pharyngitis Age Group: 17.5 Sex: M+F Population Size: 91 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	Other AEs: Vomiting... Other AEs: Vomiting (1 patient) Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598
505 mg 2 times / day multiple, oral Recommended Dose: 505 mg, 2 times / day Route: oral Route: multiple Dose: 505 mg, 2 times / day Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	unhealthy, 17.5 n = 91 Health Status: unhealthy Condition: acute streptococcal tonsilitis/pharyngitis Age Group: 17.5 Sex: M+F Population Size: 91 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	Other AEs: Rhinitis... Other AEs: Rhinitis (1 patient) Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598
506 mg 2 times / day multiple, oral Recommended Dose: 506 mg, 2 times / day Route: oral Route: multiple Dose: 506 mg, 2 times / day Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	unhealthy, 17.5 n = 91 Health Status: unhealthy Condition: acute streptococcal tonsilitis/pharyngitis Age Group: 17.5 Sex: M+F Population Size: 91 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	Other AEs: Cough... Other AEs: Cough (1 patient) Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598
507 mg 2 times / day multiple, oral Recommended Dose: 507 mg, 2 times / day Route: oral Route: multiple Dose: 507 mg, 2 times / day Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	unhealthy, 17.5 n = 91 Health Status: unhealthy Condition: acute streptococcal tonsilitis/pharyngitis Age Group: 17.5 Sex: M+F Population Size: 91 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	Other AEs: Asthenia... Other AEs: Asthenia (1 patient) Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598
2100 mg 4 times / day multiple, intravenous Studied dose Dose: 2100 mg, 4 times / day Route: intravenous Route: multiple Dose: 2100 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4936143/	healthy, 21-46 n = 10 Health Status: healthy Age Group: 21-46 Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/4936143/	Other AEs: Dizziness... Other AEs: Dizziness (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/4936143/
75 - 2400 mg 4 times / day multiple, intravenous\|intramuscular (complex) Recommended Dose: 75 - 2400 mg, 4 times / day Route: intravenous\|intramuscular Route: multiple Dose: 75 - 2400 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7017577/	unhealthy, children n = 265 Health Status: unhealthy Condition: infection Age Group: children Population Size: 265 Sources: https://pubmed.ncbi.nlm.nih.gov/7017577/	Other AEs: Diarrhoea... Other AEs: Diarrhoea (3%) Sources: https://pubmed.ncbi.nlm.nih.gov/7017577/

AEs

AE	Significance	Dose	Population
Diarrhoea	9 patients	500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	unhealthy, 17.5 n = 91 Health Status: unhealthy Condition: acute streptococcal tonsilitis/pharyngitis Age Group: 17.5 Sex: M+F Population Size: 91 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598
Abdominal pain	4 patients	501 mg 2 times / day multiple, oral Recommended Dose: 501 mg, 2 times / day Route: oral Route: multiple Dose: 501 mg, 2 times / day Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	unhealthy, 17.5 n = 91 Health Status: unhealthy Condition: acute streptococcal tonsilitis/pharyngitis Age Group: 17.5 Sex: M+F Population Size: 91 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598
Pharyngitis	3 patients	502 mg 2 times / day multiple, oral Recommended Dose: 502 mg, 2 times / day Route: oral Route: multiple Dose: 502 mg, 2 times / day Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	unhealthy, 17.5 n = 91 Health Status: unhealthy Condition: acute streptococcal tonsilitis/pharyngitis Age Group: 17.5 Sex: M+F Population Size: 91 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598
Upper respiratory infection	2 patients	503 mg 2 times / day multiple, oral Recommended Dose: 503 mg, 2 times / day Route: oral Route: multiple Dose: 503 mg, 2 times / day Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	unhealthy, 17.5 n = 91 Health Status: unhealthy Condition: acute streptococcal tonsilitis/pharyngitis Age Group: 17.5 Sex: M+F Population Size: 91 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598
Vomiting	1 patient	504 mg 2 times / day multiple, oral Recommended Dose: 504 mg, 2 times / day Route: oral Route: multiple Dose: 504 mg, 2 times / day Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	unhealthy, 17.5 n = 91 Health Status: unhealthy Condition: acute streptococcal tonsilitis/pharyngitis Age Group: 17.5 Sex: M+F Population Size: 91 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598
Rhinitis	1 patient	505 mg 2 times / day multiple, oral Recommended Dose: 505 mg, 2 times / day Route: oral Route: multiple Dose: 505 mg, 2 times / day Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	unhealthy, 17.5 n = 91 Health Status: unhealthy Condition: acute streptococcal tonsilitis/pharyngitis Age Group: 17.5 Sex: M+F Population Size: 91 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598
Cough	1 patient	506 mg 2 times / day multiple, oral Recommended Dose: 506 mg, 2 times / day Route: oral Route: multiple Dose: 506 mg, 2 times / day Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	unhealthy, 17.5 n = 91 Health Status: unhealthy Condition: acute streptococcal tonsilitis/pharyngitis Age Group: 17.5 Sex: M+F Population Size: 91 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598
Asthenia	1 patient	507 mg 2 times / day multiple, oral Recommended Dose: 507 mg, 2 times / day Route: oral Route: multiple Dose: 507 mg, 2 times / day Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	unhealthy, 17.5 n = 91 Health Status: unhealthy Condition: acute streptococcal tonsilitis/pharyngitis Age Group: 17.5 Sex: M+F Population Size: 91 Sources: https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598
Dizziness	1 patient	2100 mg 4 times / day multiple, intravenous Studied dose Dose: 2100 mg, 4 times / day Route: intravenous Route: multiple Dose: 2100 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/4936143/	healthy, 21-46 n = 10 Health Status: healthy Age Group: 21-46 Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/4936143/
Diarrhoea	3%	75 - 2400 mg 4 times / day multiple, intravenous\|intramuscular (complex) Recommended Dose: 75 - 2400 mg, 4 times / day Route: intravenous\|intramuscular Route: multiple Dose: 75 - 2400 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7017577/	unhealthy, children n = 265 Health Status: unhealthy Condition: infection Age Group: children Population Size: 265 Sources: https://pubmed.ncbi.nlm.nih.gov/7017577/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP 270

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 270	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572003/	unlikely

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:6472	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6472
MolPort	MolPort-002-507-379	https://www.molport.com/shop/molecule-link/MolPort-002-507-379
ZINC	ZINC000003982483	http://zinc15.docking.org/substances/ZINC000003982483
eMolecules	26423691	https://www.emolecules.com/cgi-bin/more?vid=26423691
eMolecules	31240769	https://www.emolecules.com/cgi-bin/more?vid=31240769

PubMed

Title	Date	PubMed
The spectrum of colitis associated with lincomycin and clindamycin therapy.	1975 May	1127264
[Letter: Cardiac arrest following the rapid intravenous injection of lincomycin].	1975 May 24	1215171
Screening for new compounds with antiherpes activity.	1984 Oct	6517562
Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro.	1996 Dec	9039272
Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium.	1997 May	9145860
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001 Nov	11792017

Patents

Sample Use Guides

In Vivo Use Guide

Intramuscular: Serious infections - 600 mg (2 mL) intramuscularly every 24 hours. More severe infections - 600 mg (2 mL) intramuscularly every 12 hours or more often. Intravenous: For serious infections doses of 600 mg (2 mL) to 1 gram are given every 8 to 12 hours. For more severe infections these doses may have to be increased. In life-threatening situations daily intravenous doses of as much as 8 grams have been given. Subconjunctival injection: 0.25 mL (75 mg) injected subconjunctivally will result in ocular fluid levels of antibacterial (lasting for at least 5 hours) with MICs sufficient for most susceptible pathogens.

Route of Administration: Other

In Vitro Use Guide

The MIC values for lincomycin were: 0.4-1.6 ug/ml (Staphylococcus aureus, 36 strains), 0.2->100 ug/ml (Staphylococcus epidermidis, 35 strains).

Name

Type

Language

LINCOMYCIN

Official Name

English

LINCOMYCIN [MI]

Common Name

English

D-ERYTHRO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE, METHYL 6,8-DIDEOXY-6-(((1-METHYL-4-PROPYL-2-PYRROLIDINYL)CARBONYL)AMINO)-1-THIO-, (2S-TRANS)-

Common Name

English

LINCOLNENSIN

Common Name

English

CLINDAMYCIN HYDROCHLORIDE IMPURITY A [IP]

Common Name

English

U-10,149

Code

English

LINCOMYCIN [ORANGE BOOK]

Common Name

English

CLINDAMYCIN HYDROCHLORIDE IMPURITY A [EP IMPURITY]

Common Name

English

U-10149

Code

English

LINCOMYCIN [GREEN BOOK]

Common Name

English

LINCOMYCIN [MART.]

Common Name

English

Lincomycin [WHO-DD]

Common Name

English

LINCOMYCIN [VANDF]

Common Name

English

LINCOMYCIN [USP IMPURITY]

Common Name

English

LINCOMYCIN [USAN]

Common Name

English

METHYL 6,8-DIDEOXY-6-((((2S,4R)-1-METHYL-4-PROPYLPYRROLIDIN-2-YL)CARBONYL)AMINO)-1-THIO-D-ERYTHRO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE

Systematic Name

English

lincomycin [INN]

Common Name

English

CLINDAMYCIN PHOSPHATE IMPURITY A [EP IMPURITY]

Common Name

English

LINCOMYCIN [HSDB]

Common Name

English

(2S-TRANS)-METHYL 6,8-DIDEOXY-6-(((1-METHYL-4-PROPYL-2-PYRROLIDINYL)CARBONYL)AMINO)-1-THIO-D-ERYTHRO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE

Common Name

English

METHYL 6,8-DIDEOXY-6-TRANS-(1-METHYL-4-PROPYL-L-2-PYRROLIDINECARBOXAMIDO)-1-THIO-D-ERYTHRO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE

Common Name

English

Classification Tree Code System Code

WHO-VATC

QJ01FF02